A Controlled Phase 2 Study for Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
Overview
- Phase
- Phase 2
- Intervention
- CLM2 topical gel
- Conditions
- Contact Lens Discomfort
- Sponsor
- Glia, LLC
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Fluorescein corneal staining
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.
Detailed Description
The clinical hypothesis is that CLM2 topical gel applied dermally on the forehead twice daily will be more effective than placebo (a) in reducing or eliminating ocular discomfort associated with contact lens wear, (b) prolong hours of comfortable wear, (c) prolong total hours of contact lens wear, (d) improve ease of insertion and removal of contact lens, and ( c) reduces friction between cornea/lens and lens/eyelid, without use of artificial eye drops or gels. One mechanism supporting this hypothesis is preliminary evidence of increased meibum secretion following CLM2 topical gel application.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female of any race ≥18 years of age at Visit 1 Screening.
- •Has provided verbal and written informed consent.
- •Be able and willing to follow instructions, including participation in all study assessments and visits.
- •Has been wearing soft contact lens in both eyes at least 2 days per week for at least a month.
- •Duration of comfortable lens wear daily is less than desired.
- •Suffers from at least two other symptoms while wearing lens with contact lens discomfort of grade 2 or higher:
- •Blurred vision
- •Conjunctival redness
- •Lens awareness
- •Use of artificial tears or gels two or more times a day during contact lens wear hours.
Exclusion Criteria
- •BCVA at baseline \<20/
- •Wearing contact lens only in one eye.
- •Wearers of the following contact lenses: Extended wear, prosthetic, scleral, and intracorneal gas permeable.
- •Pregnant women or women of childbearing potential who are not using contraception.
- •Diagnosis of the following autoimmune diseases: Addison's disease, Grave's disease, Hashimoto's thyroiditis, lupus, and Sjogren's syndrome.
- •Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such dystrophies, infections, etc.
- •Has a condition or be in a situation that, the opinion of the investigator, that may interfere significantly with the subject's participation in the study. No active ocular condition or disease.
- •Has a known adverse reaction and/or sensitivity to either study drug or its components.
- •Unwilling to remove contact lens overnight.
- •Unwilling to attempt to wear contact lens seven (7) days a week during the study period.
Arms & Interventions
CLM2 Topical Gel
CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
Intervention: CLM2 topical gel
Placebo Topical Gel
Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
Intervention: Placebo topical gel
Outcomes
Primary Outcomes
Fluorescein corneal staining
Time Frame: 21 days
Change in score (0-3 worst)
Hours of continuous comfortable contact lens wear
Time Frame: 21 days
Change in total hours per day
Berkeley Dry Eye Flow Chart
Time Frame: 21 days
Change in grade (1-5 worst)
Contact Lens Questionnaire-8 (CLDEQ-8)
Time Frame: 21 days
Change in total score (0-37 worst)
Secondary Outcomes
- Eye discomfort from CLDEQ-8, frequency(21 days)
- Eye discomfort from CLDEQ-8, intensity(21 days)
- Glia contact lens symptoms questionnaire(21 days)
- Fluorescein conjunctival staining(21 days)
- Tear film examination by TearScan(21 days)
- Tear film breakup time(21 days)
- Tear meniscus height(21 days)
- Visual acuity(21 days)
- Tear osmolarity(21 days)
- Schirmer test(21 days)